81 questions found for field 'Events'
open
⚖ 1500
Combination therapies
open
⚖ 1500
Personalized medicine
open
⚖ 1500
Blood biomarker implementation
open
⚖ 1500
Primary prevention
open
⚖ 1500
Precision prevention
open
⚖ 1500
Global implementation
open
⚖ 1500
Synaptic dysfunction markers
open
⚖ 1500
Cellular senescence markers
open
⚖ 1500
[Microbiome](/entities/microbiome) markers
open
⚖ 1500
Preventive trials
open
⚖ 1500
Outcome measure innovation
open
⚖ 1500
Global trial networks
open
⚖ 1500
Standardization
open
⚖ 1500
Accessibility
open
⚖ 1500
Integration
open
⚖ 1500
FDA-cleared alpha-synuclein SAA:
open
⚖ 1500
Improved blood SAA sensitivity:
open
⚖ 1500
Automated platforms:
open
⚖ 1500
Multiplexed panels:
open
⚖ 1500
Point-of-care development:
open
⚖ 1500
Treatment response monitoring:
open
⚖ 1500
Population screening:
open
⚖ 1500
Strain characterization:
open
⚖ 1500
Combination with genetic risk scores:
open
⚖ 1500
Therapeutic targeting of seeds:
open
⚖ 1500
Precision medicine
open
⚖ 1500
Prevention trials
open
⚖ 1500
Personalized combinations
open
⚖ 1500
Continuous monitoring
open
⚖ 1500
Global access
open
⚖ 1500
LRRK2 inhibitor approval:
open
⚖ 1500
GBA chaperone pivotal trials:
open
⚖ 1500
APOE-guided anti-amyloid therapy protocols:
open
⚖ 1500
Multi-ancestry PRS:
open
⚖ 1500
SAA-guided genetic testing:
open
⚖ 1500
Combination genetic + biomarker risk scores:
open
⚖ 1500
Gene editing for monogenic cases:
open
⚖ 1500
Preventive intervention based on genetic risk:
open
⚖ 1500
Mechanism-matched clinical trials:
open
⚖ 1500
Population screening:
open
⚖ 1500
Enhanced BBB penetration
open
⚖ 1500
Bispecific antibodies
open
⚖ 1500
Gene therapy
open
⚖ 1500
Small molecules
open
⚖ 1500
Preventive interventions
open
⚖ 1500
Precision targeting
open
⚖ 1500
Gene therapy combined with DBS
open
⚖ 1500
DBS for prodromal PD
open
⚖ 1500
Biomarker-responsive stimulation
open
⚖ 1500
Network-based targeting
open
⚖ 1500
Passive digital biomarkers
open
⚖ 1500
Continuous glucose monitoring
open
⚖ 1500
Accelerometer data
open
⚖ 1500
FDA clearance
open
⚖ 1500
Standardization
open
⚖ 1500
Accessibility
open
⚖ 1500
Integration
open
⚖ 1500
Subcutaneous formulations:
open
⚖ 1500
Anti-Aβ vaccines:
open
⚖ 1500
BACE inhibitors:
open
⚖ 1500
Small molecules:
open
⚖ 1500
Standardization
open
⚖ 1500
Clinical implementation
open
⚖ 1500
Cost-effectiveness
open
⚖ 1500
Personalized medicine
open
⚖ 1500
Precision medicine
open
⚖ 1500
Prevention trials
open
⚖ 1500
Therapeutic monitoring
open
⚖ 1500
Primary care integration
open
⚖ 1500
Early detection
open
⚖ 1500
Personalized medicine
open
⚖ 1500
Therapeutic monitoring
open
⚖ 1500
Accessibility
open
⚖ 1500
Multi-omic integration
open
⚖ 1500
Clinical implementation
open
⚖ 1500
Real-world evidence
open
⚖ 1500
Cost-effectiveness
open
⚖ 1500
FDA clearance
open
⚖ 1500
Integration with electronic health records
open
⚖ 1500
Personalized monitoring algorithms
open
⚖ 1500
Machine learning